LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (January 2022)

40 slides from LAVA Therapeutics NV's investor presentation, Jan 7, 2022

  1. Slide 1: Fighting Cancer with Precision Gammabody Platform

    Slide 1: Fighting Cancer with Precision Gammabody Platform

    1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation January 2022

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    Slide 2: Legal Disclosure: Forward-looking Statements

    2 Legal Disclosure: Forward - looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward - looking statements. Many of the forward - looking statements contain ed in this presentation can be identified by the use of forward - looking words such as “antic

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    3 Well - Funded; Experienced Leadership Lead Assets With Multiple Catalysts POC & Broad Applicability Differentiated Approach Proprietary Platform – Gammabody ™ Investment Highlights: Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers • Leaders in therapeutic bispecific antibody approach le

  4. Slide 4: Established Leadership with Proven Experience in Drug Discovery & Development

    Slide 4: Established Leadership with Proven Experience in Drug Discovery & Development

    4 Established Leadership with Proven Experience in Drug Discovery & Development Ton Adang, PhD CDO Paul Parren, PhD EVP, Head of R&D Hans van der Vliet, MD, PhD CSO Steve Hurly, MSc, MBA President & CEO • 25+ years leadership experience in life sciences industry • Former President & CEO, Sesen Bio,

  5. Slide 5: Differentiated Gammabody Pipeline in Hematologic & Solid Tumor Indications

    Slide 5: Differentiated Gammabody Pipeline in Hematologic & Solid Tumor Indications

    5 Differentiated Gammabody ™ Pipeline in Hematologic & Solid Tumor Indications MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic castration - resistant prostate cance

  6. Slide 6: Gamma Delta T Cells

    Slide 6: Gamma Delta T Cells

    6 Gamma Delta T Cells Uniquely suited for an anti - cancer T cell engager approach V  9V  2 T Cells

  7. Slide 7: Gamma Delta T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity

    Slide 7: Gamma Delta T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity

    7  T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity Adapted from Dranoff G, Nature Rev Cancer 2004; 4: 11 - 22 Kabelitz D et al., Cell Mol Immunol 2020; 17: 925 - 939 @lava therapeutics 2021 V  9V  2 T cells are a natural first line of defense against cancer, with potential

  8. Slide 8: Gamma Delta T Cells Present in Many Cancers & Correlate With Favorable Prognosis

    Slide 8: Gamma Delta T Cells Present in Many Cancers & Correlate With Favorable Prognosis

    8  T Cells Present in Many Cancers & Correlate With Favorable Prognosis Adapted from Tosolini M et al. Oncoimmunology 2017; 6, e1284723  T cells indicate highest correlation with favorable outcome among all leukocyte subsets analyzed V  9V  2 T cells are present across a wide array of hematolo

  9. Slide 9: Systemic Activation of Gamma Delta T Cells Showed Promise

    Slide 9: Systemic Activation of Gamma Delta T Cells Showed Promise

    9 Systemic Activation of V  9V  2 T Cells Showed Promise Kobayashi H et al., Cancer Immunol Immunother 2011; 60: 1075 - 1084 Wilhelm M et al., Blood 2003; 102: 200 - 206 @lava therapeutics 2021 • Systemic activation and proliferation via treatment with V  9V  2 T cell - based therapy (synthetic

  10. Slide 10: LAVA's Proprietary Gammabody Platform

    Slide 10: LAVA's Proprietary Gammabody Platform

    10 LAVA’s Proprietary Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers

  11. Slide 11: Off-the-Shelf Gammabody Platform: Enhances Innate Tumor Recognition

    Slide 11: Off-the-Shelf Gammabody Platform: Enhances Innate Tumor Recognition

    11 Off - the - Shelf Gammabody ™ Platform: Enhances Innate Tumor Recognition by Directing V  9V  2 T Cells to the Cancer Cells V  9V  2 T cells recognize stress signals – TCR interacts with pAg - butyrophilin complex Conditionally activate V  9V  2 T cells upon crosslinking with tumor associat

  12. Slide 12: Cascade Response – Potential Translation to Clinical Efficacy Benefit

    Slide 12: Cascade Response – Potential Translation to Clinical Efficacy Benefit

    12 Cascade Response – Potential Translation to Clinical Efficacy Benefit Efficacy: Safety: In addition to direct tumor cell killing , V  9V  2 T cells have the potential to orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor micro

  13. Slide 13: Potent Killing of Cancer Cells in Preclinical Models

    Slide 13: Potent Killing of Cancer Cells in Preclinical Models

    13 Potent Killing of Cancer Cells in Preclinical Models Highly Potent Durable Dose Dependent and Serial Killing Conditional Activation EGFR Gammabody ™ - Induced Cytotoxicity CD1d Gammabody ™ Triggers Lysis of CCRF - CEM Tumor Cells Killing of Primary Colorectal Cancer Cells by EGFR Gammabody TM Sus

  14. Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models

    Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models

    14 Expansion & Cascade Response Without Treg Activation in Preclinical Models Gammabody ™ can induce robust gamma delta T cell expansion and can amplify the anti - tumor immune response via downstream activation of other immune cells while avoiding co - activation of immunosuppressive T cells such a

  15. Slide 15: Potent Antitumor Effect Against Patient-Derived Tumor Tissue

    Slide 15: Potent Antitumor Effect Against Patient-Derived Tumor Tissue

    15 0 20 40 60 ✱ Potent Antitumor Effect Against Patient - Derived Tumor Tissue Using Both Autologous PBMC and Tumor - Infiltrating Lymphocytes EGFR Gammabody ™ induces potent killing of autologous cancer cells using patient derived V  9V  2 T cells Tumor - Infiltrating T cells Autologous PBMC Prim

  16. Slide 16: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells

    Slide 16: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells

    16 Gammabody TM Can Selectively Kill Cancer Cells W hile Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models Data on file: LAVA Therapeutics N.V. • 2:1 ratio (  T cells : Target cells) • Similar CD20 expression levels on C1R neo and B - cells CD20 Gammabody TM Mediated Killing P

  17. Slide 17: Fully Cross-Reactive bsTCEs are Well-Tolerated in Non-Human Primates

    Slide 17: Fully Cross-Reactive bsTCEs are Well-Tolerated in Non-Human Primates

    17 Fully Cross - Reactive  bsTCEs are Well - Tolerated in Non - Human Primates • Mild to no clinical signs of toxicity • Low cytokine spike, which did not result in CRS • No clinical chemistry abnormalities • No histopathological abnormalities • Gammabody ™ detectable on peripheral blood and lymph

  18. Slide 18: CD123 Gamma Delta T Cell Engager Vs. a CD123 Pan T Cell Engager

    Slide 18: CD123 Gamma Delta T Cell Engager Vs. a CD123 Pan T Cell Engager

    18 CD123  T Cell Engager Vs. a CD123 (CD3 - Based) Pan T Cell Engager Adapted from Ganesan et al., Leukemia 2021; 35: 2274 - 2284 @lava therapeutics 2021 Recent third - party publication compared a CD123  T cell engager to a CD123 (CD3 - based) pan T cell engager and showed similar tumor lysis c

  19. Slide 19: Gammabody Platform: Potent, Specific & Well-Tolerated

    Slide 19: Gammabody Platform: Potent, Specific & Well-Tolerated

    19 Gammabody TM Platform: Potent, Specific & Well - Tolerated High Tumor Killing Potency Tumor Specificity Conditional Activation  T cells Regulatory T Cell Activation CRS Potential Low Medium @lava therapeutics 2021

  20. Slide 20: LAVA-051 Targeting CD1d for CLL, MM & AML

    Slide 20: LAVA-051 Targeting CD1d for CLL, MM & AML

    20 LAVA - 051 Activates  T Cells and iNK T Cells by Targeting CD1d for the Treatment of CLL, MM & AML

  21. Slide 21: LAVA-051: First-in-Class Gammabody Targeting CD1d

    Slide 21: LAVA-051: First-in-Class Gammabody Targeting CD1d

    21 LAVA - 051: First - in - Class Gammabody ™ Targeting CD1d • Principal Mechanism of Action ( MoA ): Targets and activates V  9V  2 T cells in the presence of CD1d - expressing tumor cells • Secondary MoA : Activates iNKT cells against CD1d - expressing tumor cells ‒ Direct cytotoxicity against C

  22. Slide 22: LAVA-051: Targeting CD1d for Hematological Cancers

    Slide 22: LAVA-051: Targeting CD1d for Hematological Cancers

    22 LAVA - 051: Targeting CD1d for Hematological Cancers CD1d is expressed on tumors cells in a high proportion of patients with CLL, MM & AML Data on file: LAVA Therapeutics N.V. @lava therapeutics 2021 CD1d expression (MF index) Isotype Isotype Isotype 0.5 1 2 4 8 16 32 64 128 N=39 N=51 N=85 AML MM

  23. Slide 23: CD1d Gammabody induced anti-tumor activity of iNKT and gamma delta T cells

    Slide 23: CD1d Gammabody induced anti-tumor activity of iNKT and gamma delta T cells

    23 CD1d Gammabody ™ induced anti - tumor activity of iNKT and V  9V  2 T cells Gammabody ™ triggered V  9V  2 and iNKT cell activity to control CD1d+ MM tumor cell growth, resulting in substantial improvement of survival CD1d Gammabody ™ Extends Survival In Multiple Myeloma Mouse Model PBS PBS +

  24. Slide 24: Selectively Kills Cancer Cells & Spares Healthy Cells

    Slide 24: Selectively Kills Cancer Cells & Spares Healthy Cells

    24 Selectively Kills Cancer Cells & Spares Healthy Cells 2h pretreatment 50 m M ABP 30’ incubation 10pM or 1nM CD1d Gammabody TM 6h co - culture 1:1:1 ratio CLL CD1d Gammabody ™ potently killed CLL patient cells and spared healthy volunteer B cells with similar CD1d expression ex vivo Healthy B Cell

  25. Slide 25: LAVA-051 Phase 1/2a Initiated in Hematological Malignancies

    Slide 25: LAVA-051 Phase 1/2a Initiated in Hematological Malignancies

    25 CLL AND MM AML (highest dose levels only) Optional adjustments: • Dosing frequency • Dose level • # cohorts CLL (n=20) MM (n=20) Twice - weekly dosing AML (n=20) LAVA - 051 Phase 1/2a Initiated in Hematological Malignancies Data from Phase 1 expected in 1H 2022; Phase 2a dose expansion expected i

  26. Slide 26: LAVA-051 Phase 1/2a: Extensive Biomarker Analysis

    Slide 26: LAVA-051 Phase 1/2a: Extensive Biomarker Analysis

    26 Biomarker analysis to validate whether LAVA’s Gammabody ™ platform performs in humans as predicted based on preclinical data LAVA - 051 Phase 1/2a: Extensive Biomarker Analysis Pharmacodynamics Cytokines (IL - 1β, IL - 2, IL - 6, IL - 8, TNF - α, IFN - γ, GM - CSF) B inding of LAVA - 051: V  9V

  27. Slide 27: Patient Population & US Market Size in Relapsed/Refractory MM, CLL & AML

    Slide 27: Patient Population & US Market Size in Relapsed/Refractory MM, CLL & AML

    27 • PFS = 3 - 4 mos • ORR = 30 - 50% • CR = 10 - 20% • PFS = 6 - 12 mos • PFS = 4 mos 1 Decision Resources Group; Datamonitor Healthcare; Roche Investor Presentation, 2019 2 Decision Resources Group @lava therapeutics 2021 Multiple Myeloma 1 4L Efficacy, Current Standard of Care 3,4,5 * = transplan

  28. Slide 28: Feasible Threshold for Accelerated Approval Pathway in RRMM

    Slide 28: Feasible Threshold for Accelerated Approval Pathway in RRMM

    28 Feasible Threshold for Accelerated Approval Pathway in RRMM Pivotal Studies Efficacy N ORR mDOR 97 24% 4.2 mos 97 31% 11 mos 83 21% 3.8 mos @lava therapeutics 2021 PEPAXTO ( Oncopeptides ) – Feb 2021 Indication: failed ≥ 4 lines of therapy, t riple - class refractory disease BLENREP (GSK) – May 2

  29. Slide 29: LAVA-1207 Targeting PSMA for the Treatment of mCRPC

    Slide 29: LAVA-1207 Targeting PSMA for the Treatment of mCRPC

    29 LAVA - 1207 Activates  T Cells by Targeting PSMA for the Treatment of mCRPC

  30. Slide 30: LAVA-1207: Targeting PSMA for Prostate Cancer

    Slide 30: LAVA-1207: Targeting PSMA for Prostate Cancer

    30 LAVA - 1207: Targeting PSMA for Prostate Cancer • Specifically targets and mediates activation of V  9V  2 T cells against PSMA - expressing tumor cells • PSMA is a well - validated tumor target ‒ Mediates PSMA - dependent activation of V  9V  2 T cells resulting in potent killing of PSMA - p

  31. Slide 31: LAVA-1207: Targeting PSMA for Prostate Cancer

    Slide 31: LAVA-1207: Targeting PSMA for Prostate Cancer

    31 LAVA - 1207: Targeting PSMA for Prostate Cancer Butyrophilin (BTN3A) & PSMA are elevated on tumor cells in samples of prostate cancer patients PSMA is a validated target. LAVA - 1207, a PSMA Gammabody ™ , demonstrated potent, dose dependent cytotoxicity and is a potential first - in - class thera

  32. Slide 32: Unmet Need Remains In mCRPC: Initial Opportunity in 3rd Line

    Slide 32: Unmet Need Remains In mCRPC: Initial Opportunity in 3rd Line

    32 30 20 10 0 5 10 15 20 25 30 35 1L 2L 3L 2020 Treated Patients (‘000) US Treated Population 3 LAVA HCP Market R esearch 4 Product PIs Unmet Need Remains In mCRPC : Initial Opportunity in 3 rd Line 1 Decision Resources Group; Datamonitor Healthcare; AstraZeneca, Feb. 14, 2020; SVBLeerink , April 22

  33. Slide 33: LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer

    Slide 33: LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer

    33 Therapy Refractory mCRPC Optional Adjustments: • Dosing frequency • Dose level • # cohorts Therapy Refractory mCRPC (n=30) Dosing: Every 2 Weeks LAVA - 1207 Phase 1/2a in Metastatic Castration - Resistant Prostate Cancer ( mCRPC ) LAVA - 1207 Phase 1/2a Initiated; Patient Recruitment Started Dose

  34. Slide 34: Key Preclinical Programs

    Slide 34: Key Preclinical Programs

    34 Key Preclinical Programs

  35. Slide 35: Potential for LAVA-1223 Across EGFR-Expressing Solid Tumors

    Slide 35: Potential for LAVA-1223 Across EGFR-Expressing Solid Tumors

    35 Potential for LAVA - 1223 Across a Number of EGFR - Expressing Solid Tumors Data on file: LAVA Therapeutics N.V. and Janssen Biotech Inc. @lava therapeutics 2021 0 20 40 60 80 100 Bladder Breast Colon Glioma Head & Neck NSCLC Ovarian Pancreatic RCC Percentage overexpression range EGFR Expression

  36. Slide 36: CD40 Gammabody for Multiple Solid Tumors & Hematologic Malignancies

    Slide 36: CD40 Gammabody for Multiple Solid Tumors & Hematologic Malignancies

    36 CD40 Gammabody ™ for Multiple Solid Tumors & Hematologic Malignancies De Weerdt I et al., Cancer Immunol Res 2021; 9: 50 - 61 @lava therapeutics 2021 • CLL • DLBCL • MM Hematologic Malignancies Solid Tumors • Bladder • Colon • Esophageal • Lung • Ovarian • Melanoma • Renal • Pancreatic • Prostate

  37. Slide 37: dp) —@® (Ss {e) _— ep) & =

    Slide 37: dp) —@® (Ss {e) _— ep) & =

    dp) —@® (Ss {e) _— ep) & =

  38. Slide 38: Two Lead Programs in Clinic with Near-Term Milestones

    Slide 38: Two Lead Programs in Clinic with Near-Term Milestones

    38 P1: Dose Escalation • 3L+ mCRPC pts • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti - tumor activity, estimation of therapeutic window • Initial study in relapsed/refractory MM, CLL; relapsed/refractory AML added at biological relevant dose(s) • Adoptive FIH study de

  39. Slide 39: Investment Highlights

    Slide 39: Investment Highlights

    39 Well - Funded; Experienced Leadership Lead Assets With Multiple Catalysts POC & Broad Applicability Differentiated Approach Proprietary Platform – Gammabody ™ Investment Highlights: Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers • Leaders in therapeutic bispecific antibody approach l

  40. Slide 40: Fighting Cancer with Precision Gammabody Platform

    Slide 40: Fighting Cancer with Precision Gammabody Platform

    40 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation January 2022

Source: SEC EDGAR · 6-K filed Jan 7, 2022

More decks from LAVA Therapeutics NV